Development and Testing of a Smartphone Application to Reduce Substance Use and Sexual Risk Among Homeless Young Adults
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02530645|
Recruitment Status : Completed
First Posted : August 21, 2015
Last Update Posted : October 12, 2016
|Condition or disease||Intervention/treatment||Phase|
|Alcohol Use Marijuana Use Sexual Behavior||Behavioral: OnTrack Behavioral: Treatment as Usual Behavioral: Brief Motivational Interviewing||Not Applicable|
Homeless young adults have high rates of substance abuse and HIV infection and, therefore, developing effective, acceptable, and sustainable interventions to reduce their substance abuse and sexual risk behaviors is of high public health significance.
HealthCall for Smartphone (HealthCall-S) is a smartphone application originally designed for self-monitoring of alcohol use and other HIV-related health behaviors, and receiving personalized feedback on these behaviors among urban substance-abusing HIV primary care patients. Building upon prior HealthCall-S studies, individual qualitative interviews were conducted with 10 homeless young adults (age 18-21 years) at Covenant House New York (CHNY), the largest provider of crisis shelter and services for homeless young adults (age 18-21 years) in NYC. The purpose of the individual interviews was to obtain reactions to various aspects of HealthCall-S and determine how it could be adapted to better suit the needs and interests of homeless young adults. HealthCall-S has since been adapted to target alcohol use, marijuana use, and sexual risk behaviors among homeless young adults and renamed 'OnTrack.' A pilot trial (N=60) will be conducted to test the feasibility and preliminary effectiveness of OnTrack plus a brief motivational intervention (BMI), in comparison to treatment as usual (TAU) at CHNY for those with substance abuse problems and who engage in risky sex. Following referral, screening, and eligibility determination, 60 participants will complete informed consent and be randomly assigned to one of two conditions: 1) TAU or 2) OnTrack + BMI. All participants will be assessed at baseline, 2 weeks, 4 weeks, and 6 weeks after baseline to evaluate alcohol consumption, marijuana use, HIV sexual risk behaviors, and other relevant variables.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||November 2015|
|Actual Primary Completion Date :||August 2016|
|Actual Study Completion Date :||August 2016|
Experimental: OnTrack + BMI
Brief motivational interview plus the use of a smartphone application to monitor alcohol and marijuana use and sexual risk behaviors.
Behavioral: Brief Motivational Interviewing
Active Comparator: Treatment as Usual
Treatment as usual involves substance use/HIV referral and treatment as regularly offered to all participants who report substance use and sexual risk behaviors at Covenant House New York.
Behavioral: Treatment as Usual
- Alcohol use in the last 2 weeks, assessed at baseline and repeatedly so that change can be analyzed [ Time Frame: Baseline, 2, 4 (end of treatment), 6 weeks ]As measured by number of drinks per drinking day and percentage of days abstinent.
- Marijuana use in the last 2 weeks, assessed at baseline and repeatedly so that change can be analyzed [ Time Frame: Baseline, 2, 4 (end of treatment), 6 weeks ]As measured by times used marijuana per day.
- HIV sexual risk behavior in the last 2 weeks, assessed at baseline and repeatedly so that change can be analyzed [ Time Frame: Baseline, 2, 4 (end of treatment), 6 weeks ]As measured by the number of days the respondent engaged in unprotected sex.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02530645
|United States, New York|
|Covenant House New York|
|New York, New York, United States|
|Principal Investigator:||Ronald G Thompson, Ph.D.||Columbia University|